Drugs & Targets Tecentriq receives accelerated approval as initial treatment for advanced bladder cancer May 01, 2017Vol.40 No.04
Drugs & Targets FDA approves midostaurin combination for AML; Companion diagnostic also approved April 28, 2017Vol.43 No.17
Drugs & Targets FDA expands indications for regorafinib in hepatocellular carcinoma April 28, 2017Vol.43 No.17
Drugs & Targets FDA grants accelerate approval for brigatinib for ALK-positive NSCLC April 28, 2017Vol.43 No.17
Drugs & Targets FDA takes action against 14 companies for selling illegal cancer treatments April 28, 2017Vol.43 No.17
Drugs & Targets DelMar collaborates with Duke to study VAL-083 as front-line GBM treatment April 28, 2017Vol.43 No.17
Drugs & Targets Tecentriq receives accelerated approval as initial treatment for advanced bladder cancer April 21, 2017Vol.43 No.16
Drugs & Targets CTL019 receives breakthrough designation for treatment of diffuse large B-cell lymphoma April 21, 2017Vol.43 No.16
Drugs & Targets Health Canada approves Darzalex for treatment of multiple myeloma April 21, 2017Vol.43 No.16
Drugs & Targets FDA removes restrictions on use of erythropoiesis-stimulating agents April 14, 2017Vol.43 No.15
